Abstract
Plexus will report fiscal fourth-quarter 2026 results after market close (Post-Mkt) on October 28, 2026, and this preview summarizes the latest company guidance, consensus forecasts, recent financial performance, and the prevailing institutional opinions.
Market Forecast
Consensus tracking for Plexus indicates a current-quarter revenue estimate of 1.36 billion US dollars with year-over-year growth of 29.97%, adjusted EPS around 2.56 with an estimated year-over-year increase of 37.07%, and EBIT near 86.15 million US dollars with an estimated year-over-year increase of 43.62%. The company’s own guidance from the prior report called for adjusted EPS of 2.47–2.63 and revenue of 1.33–1.38 billion US dollars; margin guidance was not provided and therefore is omitted here.
The company’s main business remains diversified across three core verticals, with last quarter revenue contributions of 589.49 million US dollars from Industrial, 482.44 million US dollars from Healthcare/Life Sciences, and 232.84 million US dollars from Aerospace/Defense; management’s outlook centers on continued program ramps and disciplined cost execution. The segment with the most promising near-term traction appears to be Healthcare/Life Sciences at 482.44 million US dollars, though segment-level year-over-year growth was not disclosed; the company-level year-over-year momentum nevertheless supports a constructive view into fiscal Q4.
Last Quarter Review
Plexus delivered revenue of 1.30 billion US dollars in the prior quarter, achieved a gross profit margin of 10.07% and a net profit margin of 3.29%, produced GAAP net profit attributable to shareholders of 42.99 million US dollars, and reported adjusted EPS of 2.32, up 22.11% year over year, with revenue up 28.13% year over year.
A key highlight was execution against expectations: revenue exceeded consensus by 75.29 million US dollars and adjusted EPS surpassed estimates by 0.20, while EBIT grew 34.42% year over year; sequentially, net profit trended down 13.68%, a reminder that quarterly mix and ramp timing can still affect margins. Main-business composition remained balanced, with Industrial at 589.49 million US dollars, Healthcare/Life Sciences at 482.44 million US dollars, and Aerospace/Defense at 232.84 million US dollars; segment-level year-over-year comparisons were not disclosed, but total company growth remained robust.
Current Quarter Outlook
Main Business Execution and Revenue Mix
The current quarter centers on converting a strong backlog into revenue within the ranges the company communicated last quarter: revenue of 1.33–1.38 billion US dollars and adjusted EPS of 2.47–2.63. The market’s latest forecasts align with this band at approximately 1.36 billion US dollars in revenue and 2.56 in adjusted EPS, implying a solid year-over-year step up in both top line and earnings. Within this framework, conversion discipline and delivery timing remain crucial for sustaining the multi-quarter growth cadence and translating orders into recognized sales.
Profitability hinges on maintaining cost controls and operational leverage as program ramps progress. While last quarter’s gross margin was 10.07%, this quarter’s outlook from the company did not include a margin figure; investors are likely to monitor whether mix shifts, particularly between high-complexity programs and lower-margin builds, lift or compress the margin profile relative to last quarter. The sequential net profit dip last quarter highlights how the mix and ramp phase can temporarily pressure margins even in the context of strong year-over-year gains; a more complete ramp and stable supply-chain throughput in the current quarter could ease those pressures.
The mix across the three principal verticals remains an important driver of quarterly performance. Industrial contributed 589.49 million US dollars last quarter and remains a large revenue base that can amplify scale efficiencies when execution is consistent. Healthcare/Life Sciences at 482.44 million US dollars delivered meaningful traction, and Aerospace/Defense at 232.84 million US dollars provided additional diversification; together, these segments create multiple levers for growth. As the quarter progresses, incremental wins or accelerated ramps in either Healthcare/Life Sciences or Aerospace/Defense could support above-midpoint outcomes on the company’s revenue guidance range.
Highest-Potential Growth Engine
Healthcare/Life Sciences, with 482.44 million US dollars last quarter, appears well positioned to be a leading growth engine into this report based on the company’s balanced pipeline and the strong earnings cadence demonstrated in recent quarters. While segment-level year-over-year growth rates were not disclosed, the overall company trajectory—revenue up 28.13% year over year and adjusted EPS up 22.11%—creates a favorable backdrop for this vertical to continue contributing meaningfully. This also aligns with the broader planning and program lifecycle that typically emphasizes quality, traceability, and reliability, which benefit disciplined execution and can reinforce margin stability once new programs reach run-rate.
The second vector of upside potential is Aerospace/Defense, which accounted for 232.84 million US dollars last quarter. The smaller absolute base makes it a candidate for higher incremental growth contributions if program ramps align with customer schedules in fiscal Q4. Tactical factors such as delivery timing, factory loading, and supply-chain availability can influence how much of this potential is realized within the quarter; however, even modest outperformance here can be disproportionately accretive to margins if the mix shifts toward higher value-add content.
Industrial at 589.49 million US dollars remains the largest block of revenue and a beneficiary of operational leverage. Its scale means that even modest efficiency gains or schedule adherence can materially influence total EBIT. The company’s forecast for EBIT of approximately 86.15 million US dollars and the implied year-over-year increase of 43.62% signals that operating leverage should be supportive in the quarter, particularly if the mix avoids unexpected bottlenecks and if cost absorption improves as throughput rises.
Stock Price Drivers This Quarter
Three variables stand out as likely stock drivers around the print. The first is whether the company can deliver toward the upper half of its prior revenue range, which the market currently centers near 1.36 billion US dollars. Achieving or exceeding the midpoint tends to validate both backlog conversion and program readiness; a shortfall would prompt questions about timing and mix.
The second driver is earnings quality relative to the adjusted EPS range of 2.47–2.63 and the consensus estimate of approximately 2.56. Given last quarter’s adjusted EPS beat by 0.20 and EBIT growth of 34.42% year over year, investor attention will be on whether margin execution improves from the last quarter’s 10.07% gross margin, especially because mix and ramp phase conditions influenced sequential net profit. Gross margin directionality, even without an explicit guide, can materially shape post-report reactions.
The third driver is capital allocation and sentiment. The board’s authorization of up to 100 million US dollars in share repurchases adds flexibility in managing dilution and signaling confidence. Combined with an analyst upgrade and a consensus leaning overweight with a mean price target above current trading levels, the setup skews to how convincingly management can reinforce the fiscal Q4 trajectory and set expectations for the coming fiscal year. Any updates to program wins, delivery timing, and operating efficiency will likely be parsed closely, particularly in the context of sustaining double-digit year-over-year growth rates in revenue and EPS.
Analyst Opinions
Bullish views dominate the institutional landscape ahead of the release. One notable upgrade came from KeyBanc Capital Markets, which moved to an overweight stance and set a 300 US dollars price target, citing confidence in execution and earnings trajectory. In addition, the broader analyst cohort exhibits an overweight-leaning consensus with a mean price target around 304.60 US dollars, and the last reported quarter’s performance—adjusted EPS of 2.32 versus an approximately 2.12 consensus and revenue of 1.30 billion US dollars versus roughly 1.23 billion US dollars—supports the constructive stance. Combining the upgrade, the overweight-leaning consensus, and the above-consensus Q3 performance with stronger-than-expected Q4 guidance from the company yields a tally of three bullish indications and no offsetting bearish calls in the covered period, suggesting a majority bullish ratio of 3:0.
The bullish case emphasizes three pillars. First, guidance for fiscal Q4 that framed revenue at 1.33–1.38 billion US dollars and adjusted EPS at 2.47–2.63 positively reset expectations above many prior models, and current consensus aligns with this constructive tone at approximately 1.36 billion US dollars and 2.56, respectively. Second, execution momentum—highlighted by last quarter’s revenue beat of 75.29 million US dollars and adjusted EPS beat of 0.20—alongside EBIT growth of 34.42% year over year, suggests operating leverage is tracking ahead of earlier assumptions. Third, capital return flexibility via the recently authorized 100 million US dollars share repurchase plan provides an incremental support mechanism for EPS and a signaling tool that can underpin valuation in periods of market volatility.
Analysts in the bullish camp describe a tangible path for the quarter: consensus revenue at 1.36 billion US dollars maps directly to the midpoint of the company’s outlook, and the modeled adjusted EPS of 2.56 implies healthy conversion of incremental revenue to earnings, even if gross margin remains around the prior-quarter level. They view upside risk in the event that mix tilts favorably or that program ramps move in more quickly than expected. On the other hand, they acknowledge that sequential variability in net profit, such as last quarter’s 13.68% decline, is a feature of program ramp dynamics; however, strong year-over-year growth in both revenue and earnings is seen as the more relevant anchor for valuation.
The majority opinion also highlights that the current forecast includes meaningful year-over-year growth rates: revenue up 29.97%, adjusted EPS up 37.07%, and EBIT up 43.62%. These modeled outcomes leave room for debate about the distribution between the three end markets, but they collectively anchor a thesis that the company’s delivery cadence and cost structure are aligned with the elevated guidance path. The setup gives management an opportunity to reiterate visibility into key programs and to frame the early quarters of the next fiscal year.
In summary, the prevailing analyst view is constructive heading into October 28, 2026. The combination of above-trend growth, consistent execution against guidance, and capital allocation flexibility supports a bullish stance for the print. The core questions revolve around mix, margin directionality relative to last quarter’s 10.07%, and the cadence of program ramps; positive resolution on any two of these is seen as sufficient to sustain the earnings trajectory implied by a 1.36 billion US dollars revenue run-rate and an adjusted EPS profile around 2.56 for fiscal Q4.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments